962 Shares in Revvity, Inc. (NYSE:RVTY) Bought by Murphy & Mullick Capital Management Corp

Murphy & Mullick Capital Management Corp bought a new position in shares of Revvity, Inc. (NYSE:RVTY) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 962 shares of the company’s stock, valued at approximately $107,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RVTY. Vanguard Group Inc. lifted its holdings in shares of Revvity by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 14,290,211 shares of the company’s stock valued at $1,594,930,000 after purchasing an additional 156,679 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Revvity during the 4th quarter worth approximately $4,777,000. Millstone Evans Group LLC bought a new position in Revvity in the fourth quarter valued at approximately $38,000. Royal London Asset Management Ltd. boosted its holdings in shares of Revvity by 15.5% in the fourth quarter. Royal London Asset Management Ltd. now owns 50,437 shares of the company’s stock valued at $5,629,000 after buying an additional 6,770 shares during the period. Finally, Generali Investments Management Co LLC bought a new stake in shares of Revvity during the fourth quarter worth $385,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Price Performance

NYSE:RVTY opened at $107.42 on Thursday. The stock has a market capitalization of $12.91 billion, a PE ratio of 48.61, a P/E/G ratio of 3.82 and a beta of 1.06. Revvity, Inc. has a 1-year low of $97.32 and a 1-year high of $129.50. The firm has a fifty day simple moving average of $115.66 and a 200 day simple moving average of $117.35. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the prior year, the firm posted $1.25 earnings per share. On average, research analysts expect that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be given a $0.07 dividend. The ex-dividend date is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.26%. Revvity’s payout ratio is 12.67%.

Analyst Ratings Changes

RVTY has been the topic of several research reports. Bank of America raised shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price objective on the stock in a research report on Friday, December 13th. Sanford C. Bernstein cut Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective for the company. in a research report on Friday, January 10th. Barclays increased their price objective on Revvity from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Raymond James restated an “outperform” rating and issued a $145.00 target price (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Finally, KeyCorp raised their price target on shares of Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $136.25.

Insider Transactions at Revvity

In other news, insider Tajinder S. Vohra sold 5,492 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. This trade represents a 21.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Joel S. Goldberg sold 15,170 shares of Revvity stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now directly owns 33,400 shares of the company’s stock, valued at $4,232,782. The trade was a 31.23 % decrease in their position. The disclosure for this sale can be found here. 0.68% of the stock is currently owned by corporate insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.